McCulloch Kevin sold $723K of XERS
McCulloch Kevin (See Remarks) sold 90,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.03 ($0.72M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
An officer sold 90,000 shares at $8.0279/share under a pre-arranged 10b5-1 plan; this is typically informational rather than a fundamental catalyst.
Market read
Traders may note the sale for sentiment monitoring, but the planned nature and modest dollar value relative to company fundamentals usually limit tradable impact.
What to watch
The filing does not state motives, tax needs, or whether sales are part of a broader cadence; without additional context, signal quality is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Xeris Biopharma Holdings, Inc.
Ticker impact
Xeris Biopharma disclosed an officer open-market sale of 90,000 shares at $8.0279 on a 10b5-1 plan, totaling about $722.5K.
Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.
The article provides only an insider transaction size and price, and explicitly notes a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
No sector-level implications are disclosed; this is company-specific insider trading data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may still monitor for follow-on disclosures.
Key entities
- issuerXeris Biopharma Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderMcCulloch Kevin
Officer who executed the open-market sale under a 10b5-1 plan.